24.3 C
New York
Monday, June 27, 2022

Rovi aims to address an annual market of 2.9 million breast cancer treatments

- Advertisement -
- Advertisement -

Rovi is already working on what could be its future big leap thanks to a new drug. The company expects to address an annual market of 2.9 million breast cancer treatments with its extended-release drug, Letrozole-ISM.

The Madrid laboratory, recently recognized as Moderna’s partner for the manufacture of the North American company’s Covid-19 vaccine, received approval in February to commercialize its first sustained-release drug in Europe, in this case for schizophrenia, dubbed Okedi . The company has already started distributing this medicine in Germany and will shortly do so in the UK and Spain.

Okedi and Letrozole-ISM for breast cancer are both based on Rovi’s proprietary ISM drug delivery platform. It is a technology that can be applied to various drugs to reduce the number of doses required and improve the level of patient compliance with prescribed treatment, among other benefits.

In the case of letrozole-ISM, the company has already completed Phase I clinical trials in patients and is waiting to know when it will advance to the following phases, data not shared by the public company and controlled by the López family Belmonte.

“We face a challenge of being the first company to develop this type of drug for women,” said Javier López-Belmonte, Rovi’s vice president, at the company’s shareholder meeting last week as he commented on the future market for this investigational drug referred. It would be, as in the case of Okedi for schizophrenia, replacing current daily pills of hormone treatment for breast cancer with sustained-release injection therapy that can last several months. “Apply this technology that can enable the doctor to ensure therapeutic compliance with the drug,” said the manager.

Rovi has not commented on the market volume for this drug, but points out, for example, that in prostate cancer, where these prolonged-release solutions already exist, this type of therapy has captured 89% of a $2,500 million market in the US and Europe, according to data from the consultancy Iqvia collected by Rovi.

Letrozole is the reference treatment for the most common hormone receptor-positive breast cancer, which affects between 60% and 65% of patients, according to Rovi. The lab uses an already used and tested drug like letrozole to deliver it through its technology. “Our product can be just as effective as the original drug,” says López-Belmonte, and he believes that his solution can work with a smaller amount of active ingredient, which would lead to fewer side effects.

“We are the company that, thanks to our technology, has gone the furthest in this development. There is no product of this type on the market,” was affirmed in front of the shareholders.


Source elpais.com

- Advertisement -

New Articles